American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 197-202 , August 2007

Diuretics Are Preferred Over Angiotensin II-Converting Enzyme Inhibitors For Initial Therapy of Uncomplicated Hypertension

    Con
  • Vito M. Campese, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Vito M. Campese, MD, Division of Nephrology, and Hypertension Center, Keck School of Medicine, USC, 1200 North State St., Los Angeles, CA 90033.

References 

  1. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. New Engl J Med. 1981;304:930–933
  2. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2572
  3. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277:739–745
  4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (Final results of the Systolic Hypertension in the Elderly Program (SHEP)). JAMA. 1991;265:3255–3264
  5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  6. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755–1762
  7. Turnbull F Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003;362:1527–1535
  8. Wing LMH, Reid CM, Ryan P, et al. Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348:583–592
  9. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352–358
  10. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  11. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004–1010
  12. Wilkins RW. New drugs for the treatment of hypertension. Ann Intern Med. 1959;50:1–10
  13. Goldner MG, Zarowitz H, Akgun S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. N Engl J Med. 1960;262:403–405
  14. Houston MC. The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J. 1988;115:640–656
  15. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium and the development of diabetes (A quantitative review). Hypertension. 2006;48:219–224
  16. Punzi HA, Punzi CF. Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study. Curr Hypertens Rep. 2004;6:106–110
  17. Sierra C, Ruilope LM. New-onset diabetes and antihypertensive therapy: comments on ALLHAT trial. J Renin Angiotensin Aldosterone Syst. 2003;4:169–170
  18. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963–969
  19. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2005;165:1401–1409
  20. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95:29–35
  21. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (Final results of the Systolic Hypertension in the Elderly Program (SHEP)). JAMA. 1991;265:3255–3264
  22. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906
  23. Staessen JA, Thijs L, Birkenhäger WH. Noncardiovascular Illness as Barrier to Antihypertensive Treatment. Hypertension. 2005;46:255–256
  24. Moser M. The ASCOT Trial (Commentary). J Clin Hypertens. 2005;7:748–750
  25. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003;361:1149–1158
  26. Sever P, Dahlöf B, Poulter N, et al. ASCOT Steering Committee Members Potential synergy between lipid-lowering and blood-pressure lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982–2988
  27. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560–2572
  28. Cutler JA. Thiazide-associated glucose abnormalities: Prognosis, etiology, and prevention (Is potassium balance the key?). Hypertension. 2006;48:198

PII: S0272-6386(07)00927-4

doi: 10.1053/j.ajkd.2007.06.005

American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 197-202 , August 2007

Article Tools